Enrollment complete in lead-in portion of eravacycline trial


Tetraphase Pharmaceuticals (TTPH) completes patient enrollment in the lead-in portion of its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline for the treatment of complicated urinary tract infections. The lead-in section's purpose is to inform the selection of an oral dose to take forward into the pivotal portion of the trial.

The company expects to report top-line data in Q3.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs